GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH.

ABSTRACT:

Background & aims

Steatotic liver disease can lead to the development of metabolic dysfunction-associated steatohepatitis (MASH), the prevalence of which is rapidly increasing, intensifying the need to find an effective treatment. GTX-11 is a first-in-class drug with anti-inflammatory and antifibrotic properties mediated by the modulation of the transforming growth factor beta pathway. The present study evaluated the effects of GTX-11 on hepatic hemodynamics and liver fibrosis, as well as its underlying mechanisms, in a preclinical model of MASH, and in human precision-cut liver slices (hPCLS).

Methods

Male Wistar MASH rats received GTX-11 (1 and 10 mg/kg/day) or vehicle, for 14 days (n = 15/group). In vivo systemic and hepatic hemodynamics, fibrosis, biochemical para

SUBMITTER: Andres-Rozas M 

PROVIDER: S-EPMC12447985 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature